A controlled trial of aerosolized pentamidine or trimethoprim-sulfamethoxazole as primary prophylaxis against Pneumocystis carinii pneumonia in patients with human immunodeficiency virus infection. The Dutch AIDS Treatment Group

The New England Journal of Medicine
M M SchneiderJ C Borleffs

Abstract

Primary prophylaxis against Pneumocystis carinii pneumonia (PCP) is recommended for patients with human immunodeficiency virus (HIV) infection if their CD4 cell counts are below 200 per cubic millimeter (0.2 x 10(9) per liter). Either aerosolized pentamidine or trimethoprim-sulfamethoxazole (co-trimoxazole) is commonly prescribed for prophylaxis, but the relative efficacy and toxicity of these agents are unknown. We conducted a multicenter trial involving 215 HIV-infected patients with no history of PCP but with CD4 cell counts below 200 per cubic millimeter. The patients were randomly assigned to one of three regimens: aerosolized pentamidine once a month, 480 mg of trimethoprim-sulfamethoxazole once a day (80 mg of trimethoprim and 400 mg of sulfamethoxazole), or 960 mg of trimethoprim-sulfamethoxazole once a day (160 mg and 800 mg, respectively). The cumulative incidence of PCP was estimated by Kaplan-Meier survival analysis. After a mean follow-up of 264 days, 6 of the 71 patients in the pentamidine group had a confirmed first episode of PCP (11 percent), whereas none of the 142 patients in the two trimethoprim-sulfamethoxazole groups had PCP (P = 0.002). However, adverse events that required discontinuation of the medicati...Continue Reading

References

Jan 1, 1995·Pediatric Pulmonology. Supplement·M R Bye
Apr 15, 2008·Journal of the Association for Research in Otolaryngology : JARO·Lynn L ChiuHenry C Ou
Feb 1, 1997·Journal of General Internal Medicine·M D WenrichP G Ramsey
Dec 9, 1995·Health Policy·M G DijkgraafJ C Jager
Jan 1, 1995·The American Journal of Medicine·P DomingoM A Sambeat
Apr 1, 1995·The American Journal of Medicine·S B Wilkinson
Apr 3, 2003·Cancer Treatment Reviews·Beela S Mathew, Stuart A Grossman
Feb 4, 1998·Critical Care Clinics·C F Decker, H Masur
Jan 6, 2001·Infectious Disease Clinics of North America·W Tantisiriwat, W G Powderly
Oct 1, 1994·Baillière's Clinical Endocrinology and Metabolism·F G BrivetJ Dormont
May 1, 1997·Nuclear Medicine and Biology·S H ThomasM J O'Doherty
Oct 13, 2000·Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology·S YoshizawaS Oka
Nov 1, 1996·Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology·V KalanadhabhattaM Kramer
Dec 24, 1992·The New England Journal of Medicine·H Masur
Mar 25, 1993·The New England Journal of Medicine·J Chakrabarti
May 20, 1993·The New England Journal of Medicine·S E Weinberger
Dec 23, 1993·The New England Journal of Medicine·D R HooverR A Kaslow
Mar 16, 1995·The New England Journal of Medicine·N Clumeck
May 11, 2000·The New England Journal of Medicine·J A Kovacs, H Masur
Dec 10, 1999·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·E RiberaA Pahissa
Oct 12, 2001·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·S AbgrallClinical Epidemiology Group of the French Hospital Database on HIV
Jun 1, 1997·Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology : Official Publication of the International Retrovirology Association·H C BucherM Opravil
Dec 22, 1998·Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology : Official Publication of the International Retrovirology Association·S L WalmsleyO Djurdjev
Jun 1, 1995·Journal of Clinical Pharmacy and Therapeutics·A E Jolley, J G Hastings
Apr 18, 2002·Antimicrobial Agents and Chemotherapy·Aaron L Baggish, David R Hill
Feb 1, 1995·Thorax·R F Miller, D M Mitchell
Jul 2, 2002·Infectious Diseases in Obstetrics and Gynecology·US Public Health Service, Infectious Diseases Society of America, Prevention of Opportunistic Infections Working Group

Citations

Aug 17, 1991·Lancet·A J van der VenJ W van der Meer
Sep 5, 1991·The New England Journal of Medicine
Apr 18, 1991·The New England Journal of Medicine·B HirschelV Gabriel
Feb 1, 1991·The Journal of Antimicrobial Chemotherapy·R F Miller, S Steel
May 1, 1990·Reviews of Infectious Diseases·E E TelzakD Armstrong
Nov 1, 1989·The Journal of Infectious Diseases·J A Kovacs, H Masur
Feb 26, 1988·JAMA : the Journal of the American Medical Association·M A FischlL La Voie
Jun 2, 1988·The New England Journal of Medicine·A E GlattS H Landesman
Jun 25, 1987·The New England Journal of Medicine·W T HughesL Lott

Related Concepts

Tumor Virus Infections
Trimethoprim
Pneumocystis Infections
HIV Infections
Differential White Blood Cell Count Procedure
Adverse Event
CD4 Count Determination Procedure
Once A Day
Pneumocystis Jiroveci Pneumonia
Aerosol Dose Form

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Synapse Loss as Therapeutic Target in MS

As we age, the number of synapses present in the human brain starts to decline, but in neurodegenerative diseases this occurs at an accelerated rate. In MS, it has been shown that there is a reduction in synaptic density, which presents a potential target for treatment. Here is the latest research on synapse loss as a therapeutic target in MS.

Artificial Intelligence in Cardiac Imaging

Artificial intelligence (ai) techniques are increasingly applied to cardiovascular (cv) medicine in cardiac imaging analysis. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

Social Learning

Social learning involves learning new behaviors through observation, imitation and modeling. Follow this feed to stay up to date on the latest research.

Cell Atlas of the Human Eye

Constructing a cell atlas of the human eye will require transcriptomic and histologic analysis over the lifespan. This understanding will aid in the study of development and disease. Find the latest research pertaining to the Cell Atlas of the Human Eye here.

Single Cell Chromatin Profiling

Techniques like ATAC-seq and CUT&Tag have the potential to allow single cell profiling of chromatin accessibility, histones, and TFs. This will provide novel insight into cellular heterogeneity and cell states. Discover the latest research on single cell chromatin profiling here.

Genetic Screens in iPSC-derived Brain Cells

Genetic screening is a critical tool that can be employed to define and understand gene function and interaction. This feed focuses on genetic screens conducted using induced pluripotent stem cell (iPSC)-derived brain cells.